Natalizumab January 2012 PML Update




Another way of looking at the risk is to inverse the figures; for example 10.6/1000 = 1 person in 94, who is JCV seropositive, has received previous immunosuppression, and has had 25 to 48 infusions of natalizumab, will develop PML. 


Source: Biogen-Idec


CoI: Multiple